Our leaders combine over 85 years of experience in the healthcare and pharmaceutical industry.
Together our team launched the first vaginal pH modulator, a unique mechanism of action, to bring much-needed non-hormonal innovation to the contraceptive space with Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.
Saundra Pelletier
Chief Executive Officer
Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2021. She has been responsible for the company’s growth and evolution, led Evofem’s transition to the public market in January 2018, and led multiple equity financing rounds which have raised over $500 million.
Ivy Zhang
Chief Financial Officer and Secretary
Ivy Zhang is a trusted leader and seasoned finance executive with more than 14 years of financial and accounting experience spanning diverse industries, including pharmaceuticals and medical devices, who is dedicated to advancing Evofem Biosciences’ mission of addressing the unmet sexual and reproductive health needs of women. She joined Evofem as Chief Financial Officer and Secretary in April 2023 and leads the Company’s finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions.
Kathy Gallo-Doyle
SVP, Commercial Operations
Kathy joined Evofem in January 2021 as Vice President of Sales. She has been responsible for effectively designing and executing sales force strategies to drive significant revenue growth and an optimal sales team. She specializes in aligning sales initiatives with corporate goals and building and leading high-performing sales teams that succeed through a culture of inclusion, collaboration, and engagement.
Amy Raskopf
Chief Business Development Officer
Since joining Evofem in 2018, Amy has progressively advanced to senior leadership roles, culminating in her appointment as Chief Business Development Officer in 2024. In this capacity, she successfully established the company’s first ex-U.S. commercial agreement for Phexxi® (lactic acid, citric acid, and bitartrate), paving the way for the hormone-free contraceptive’s entry into the UAE and other GCC markets. Additionally, she spearheaded Evofem’s acquisition of SOLOSEC® (secnidazole) 2g granules, an FDA-approved single-dose oral antibiotic for two common sexual health conditions.
Ellen Thomas
Chief of Staff
Ellen Thomas, Evofem Biosciences’ Chief of Staff, has over 30 years of professional experience in board management and corporate governance, healthcare communications, global operations, marketing, thought leader engagement, global meeting/conference event management, pharmaceutical sales, continuing medical education and management consulting. She joined Evofem in January 2013 and has worked for Saundra Pelletier since July 2009.